Business
Who Will Be Able to Take the Breakthrough Drug for Postpartum Depression?
Just approved by the FDA, Zulresso is costly and must be administered in a certified facility.
This article is for subscribers only.
Zulresso, the world’s first-ever drug for postpartum depression, cleared a major hurdle when it won approval from the Food and Drug Administration this week. Even bigger challenges lie ahead for Sage Therepeutics Inc., the drug’s developer.
Zulresso, the brand name for brexanolone, works much faster to treat the condition than anything currently available. Experts have hailed it as “groundbreaking,” a “game changer.” And postpartum depression affects as many as one in nine new mothers. These facts alone would suggest the drug is destined to be a blockbuster. Yet there’s a difference between a drug that works and a drug that sells.